



CVCT MEMA 2018



In collaboration with



13-14 September 2018
Intercontinental Semiramis Hotel
Cairo, Egypt



WELCOME MESSAGE

We are delighted to welcome you in Cairo in CVCT MEMA, 13-14 September 2018

CVCT MEMA, the single event assembling a think tank of high profile multiple stakeholder experts aiming at producing, promoting and applying evidence-based Cardiovascular medicine in the Region

CVCT meetings are oriented toward brainstorming and intense interaction, among leaders from various backgrounds assembling in a unique think tank. Rather than simple lecturing, and beyond the educational aims, sessions provide ample time for panel discussion among the think tank members and with delegates. Pharmaceutical and health industry should view this initiative differently from a simple promotional/educational meeting.

Supporting/attending CVCT will contribute to better understanding local health care systems and governmental policies, disease burden, clinical practice patterns and unmet needs as well as ways for the optimal implementation of major recent therapeutic innovations.

The CVCT MEMA Forum follows the successful example of the main CVCT meetings in Paris, Singapore and Washington DC, (globalcvctforum.com) which enjoy large representation from Europe, the US and Asia.

CVCT-MEMA aims to bring together top Middle East and African cardiovascular trialists, investigators, statisticians, industry R&D experts, national regulators and practitioners across the region.

CVCT meetings have become a new energetic and motivating unique type of meeting. The specific aim is to examine important and timely CV trial issues relating to methodology, interpretation, approval and implementation of recent, ongoing and future trials in specific CV therapeutic areas.

We hope you will enjoy and benefit from this unique event

CVCT MEMA Board

CVCT MEMA Board



Prof. Faiez Zannad

Founder & Chairman



Prof. Mohamed Sobhy

Co-Chairman



Prof. Habib Gamra

Co-Chairman

Under Patronage of

H.E. Prof.


Khaled Abdel Ghaffar

Minister of Higher Education &
Scientific Research

H.E. Prof.

Hala Zaid

Ministry of Health and Population



CVCT MEMA FACULTY

IN ALPHABETICAL ORDER

Adel El Adawy, Egypt

Ahmed Abdel Raouf, Sanofi,
Egypt

Ahmed Elghalid, Egypt

Ahmed Khalaf, Amgen, Egypt

Alexander Mebazaa, France

Ali Oto, Turkey

Amin Fouad, Egypt

Amr Elhadidy, Egypt

Amr Kamal, Egypt

Amr Saad, Cairo Egypt

Amr Zaki, Egypt

Ashraf El Fiky, USA

Ashraf Hatem, Egypt

Ashraf Shehata, Pfizer, Egypt

Azza Saleh, Egypt

Chokri Jeribi, Sanofi, Tunisia

Dina Shokry, Egypt

Elsayed Farag, Egypt

Faiez Zannad, France

Fatima Cassim, AstraZeneca,
South Africa

Fouad El Nawawy, Egypt

Gamal Shaaban, Egypt

Gamila Nasr, Egypt

Gehan Ramadan, Novartis, Egypt

George Saade, Lebanon

Gershim Asiki, Kenya

Ghassan Kiwan, Lebanon

Habib Gamra, Tunisia

Hadi Abu Hantash, Jordan

Haitham Badran, Egypt

Hala Ramzy, SANOFI, Egypt

Hany Ragy, Egypt

Hany Sleem, Egypt

Harun Otieno, Kenya

Hazem Khamis, Egypt

Hesham Aboul Enein, Egypt

Hesham Salah, Egypt

Hosam Hasan, Egypt

Ines Fradi, Tunisia

Ines Khochtali, Tunisia

Karim AbdelHady, Amgen, Egypt

Khaled Shokry, Egypt

Luis Ruilope, Spain

Maciej Kostrubic, UK

Magdy Abdel Hamid, Egypt

Magdy El Masry, Egypt

Mahmoud Hassanein, Egypt

Manal Milhe, USA

Manal Milhem, USA

Maurizio Gasparini, Italy

Michael Nabil, Sanofi, Egypt

Moataz Zaki, Egypt

Mohamed Balghaith, KSA



CVCT MEMA FACULTY

IN ALPHABETICAL ORDER

Mohamed Gamal, Egypt

Mohamed Hsairi, Tunisia

Mohamed Sanhoury, Egypt

Mohamed Sleem, Egypt

Mohamed Sobhy, Egypt

Mosaad Morsi, Ray, Egypt

Mouez Ben Ali, Novartis Europe,
France

Nabil Elkafrawy, Egypt

Nabil Farag, Egypt

Nancy Awad, IQVIA, UAE

Nihal El Habachi, Egypt

Omer Goktekin, Turkey

Ramzy El Mawardy, Egypt

Sahar Ebrahim, IQVIA, Egypt

Salah El Tahan, Egypt

Sameh Emil, Egypt

Tabassome Simon, France

Wael Al Mahmeed, UAE

Walid Ammar, Egypt

Zainab Samad, Pakistan and USA

GENERAL INFORMATION

Meeting Venue

Intercontinental Semiramis Hotel, Egypt

Main Hall: Teeba Meeting Room

Regulatory Summit: Pavilion Meeting Room



Housing

Intercontinental Semiramis Hotel, Egypt

All rooms are on bed & breakfast basis

Check in Time 2:00 p.m. - Check out Time 12:00 p.m.



Electricity

The electricity supply in Egypt is 220 Volts, 50 Hz.

Most hotels also provide 110 Volts outlets for shavers



Currency Banking

(rates are subjects to market fluctuations)

Egyptian Pound (EGP) is the official currency in Egypt.

Foreign currency exchange is available in most of the hotels, banks and currency exchange offices.

ATM machines are available all through the city, at the convention center and at the vicinity of all Meeting hotels



GENERAL INFORMATION

Language

The official language is English.

All lectures and presentations will be held in the English language only.

There will be no translation available

Meals Timings

<i>Thursday, 13 SEP 2018</i>	<i>Coffee Break</i>	<i>12:00-12:30</i>
	<i>Lunch</i>	<i>16:30-17:00</i>
<i>Friday, 14 SEP 2018</i>	<i>Coffee Break</i>	<i>14:00-14:30</i>
	<i>Lunch</i>	<i>16:00-16:30</i>

Registration Hours

Thursday, 13 SEP 2018, from 8:30 till 17:30

Friday, 14 SEP 2018, from 8:30 till 18:30

Scientific Hours

Thursday, 13 SEP 2018, from 10:00 till 19:00

Friday, 14 SEP 2018, 9:00 till 18:00

GENERAL INFORMATION

Badge

All registrants must wear their name badge to have access to forum sessions.

Barcode

*Barcode will be printed on all badges of participants.
All access to Halls of the Meeting will be with the badge.
Please make sure that you scanned your badge before every session, as this is the only way to assure your attendance and taking your certificate*

Website

www.cvctmiddleeast.com



Facebook Page

CVCT - MEMA



CERTIFICATION

Attendance of all program sessions is mandatory to be legible to receive your certificate.

Please make sure that you scanned your badge before every session, as this is the only way to assure your attendance and taking your certificate


Attendance Certificate will be delivered to all delegates on Friday, 14th of September 2018 from Registration Desk from 17:30-18:00

ACKNOWLEDGEMENT





SCIENTIFIC AGENDA





Clinical research in Middle East, Mediterranean and Africa (MEMA)

Clinical research provides robust ways of investigating the safety, clinical benefit and cost effectiveness of treatments, interventions, or other aspects of healthcare provision. Health policy and health industry decision-making and investment, shaping up sustainable and responsible health care systems should rely on optimal quality health data. The contribution of Middle East, Mediterranean and Africa (MEMA) region to high standard health knowledge and actionable data is an important unmet need. Health policy and clinical practice in these regions should improve to be more data driven and more evidence based as to offer better and more cost-effective health care to the patients in the Region. Obviously, healthcare in the Region cannot be driven by the simple transposition of evidence and health data collected in high income and/or Northern/Western countries. Increasing the contribution of local investigators and health care professionals to the global clinical research effort and generating a genuine local clinical research is an important priority for all health care professionals and policy makers in the Region. Cardiovascular disease is one of the medical areas where practice is most driven by robust clinical evidence, stemming from well-designed clinical trials. The experience accumulated by international and local experts in this area may serve as a case study starting point, which may be applied to other disease areas.

THURSDAY, 13 SEPTEMBER 2018

DAY 1: CVCT Forum Main Hall: Teeba Meeting Room

GAME-CHANGER TRIALS OF THE YEAR

NEW TRIAL DATA, AND HOW THESE SHOULD INFLUENCE DAILY PRACTICE

10:00-12:00

**Prevention and Cardiovascular Risk Factors, Hypertension, Diabetes and
Dyslipidemia**

Chairpersons: *(in alphabetical order)*

Amin Fouad, Egypt - Fouad El Nawawy, Egypt - George Saade, Lebanon - Hazem Khamis, Egypt - Hesham Aboul Enein, Egypt - Hesham Salah, Egypt - Luis Ruilope, Spain - Mahmoud Hassanein, Egypt - Mohamed Gamal, Egypt - Mohamed Sobhy, Egypt - Nabil Elkafrawy, Egypt - Wael Almahmeed, UAE

10:00 – 10:30 Regional perspective:

Elsayed Farag (Zagazig, Egypt)
Ines Khochtali (Monastir, Tunisia)
Gershim Asiki (Nairobi, Kenya)

10:30 – 11:10 Industry perspective:

Fatima Cassim (AstraZeneca, South Africa)
Mohamed Sobhy (Alexandria, Egypt) – Amgen Perspective
Mohamed Sobhy (Alexandria, Egypt) – SANOFI Perspective

11:10 – 11:30 International perspective:

Faiez Zannad (Nancy, France)
Luis Ruilope (Madrid, Spain)



11:30 – 12:00 Panel Discussion: Are there strategies of CVD prevention in the region? – How can we adapt/ adopt international guidelines for CVD prevention and CVRF control in the region?

Panelists: *(in alphabetical order)*

Ahmed Abdel Raouf, Sanofi, Egypt - Ahmed Khalaf, Amgen, Egypt - Amin Fouad, Egypt - Elsayed Farag, Egypt - Faiez Zannad, France - Fatima Cassim, AstraZeneca, South Africa, Fouad El Nawawy, Egypt - Gershim Asiki, Kenya - George Saade, Lebanon - Hala Ramzy, Sanofi, Egypt - Hazem Khamis, Egypt - Hesham Aboul Enein, Egypt - Hesham Salah, Egypt - Ines Khochtali, Tunisia – Karim AbdelHady, Amgen, Egypt - Luis Ruilope, Spain - Mahmoud Hassanein, Egypt - Mohamed Gamal, Egypt - Mohamed Sobhy, Egypt - Nabil Elkafrawy, Egypt - Wael Almahmeed, UAE

12:00 – 12:30 Coffee break

12:30 – 13:30

Opening Ceremony and Press Conference

13:30 – 15:00

Interventional cardiology, ischemic heart disease, thrombotic diseases

Chairpersons: *(in alphabetical order)*

Ahmed Elghalid, Egypt - Amr Elhadidy, Egypt - Amr Zaki, Egypt - Gamila Nasr, Egypt - Georges Saade, Lebanon - Hadi Abu Hantash, Jordan - Hosam Hasan, Egypt - Mohamed Balghaith, KSA - Mohamed Sleem, Egypt - Mohamed Sobhy, Egypt - Sameh Emil, Egypt - Tabassome Simon, France

13:30 – 14:00 Interventional cardiology in ischemic heart disease

Omer Goktekin (Istanbul, Turkey)
Habib Gamra (Monastir, Tunisia)
Mohamed Sobhy (Alexandria, Egypt)

14:00 – 14:30 Thrombotic diseases

Tabassome Simon (Paris, France)
Georges Saade (Beyrouth, Lebanon)
Magdy Abdelhamid, (Cairo, Egypt) – AstraZeneca Perspective

14:30 – 15:00 Panel Discussion: What recent trials in interventional cardiology will change our practice?

Panelists: *(in alphabetical order)*

Ahmed Elghalid, Egypt - Amr Elhadidy, Egypt - Amr Zaki, Egypt - Ashraf Shehata, Pfizer, Egypt - Gamila Nasr, Egypt - Georges Saade, Lebanon - Habib Gamra, Tunisia - Hadi Abu Hantash, Jordan - Hosam Hasan, Egypt - Mohamed Balghaith, KSA - Mohamed Sleem, Egypt - Mohamed Sobhy, Egypt - Omer Goktekin, Turkey - Sameh Emil, Egypt - Tabassome Simon, France

15:00 – 16:30

Interventional cardiology, devices and structural heart disease

Chairpersons: *(in alphabetical order)*

Ali Oto, Turkey - Amr Kamal, Egypt - Elsayed Farag, Egypt - Habib Gamra, Tunisia
- Hadi Abu Hantash, Jordan - Haitham Badran, Egypt - Khaled Shokry, Egypt -
Nabil Farag, Egypt - Maurizio Gasparini, Italy - Mohamed Balghaith, KSA -
Mohamed Sanhoury, Egypt - Mohamed Sobhy, Egypt - Zainab Samad, Pakistan
and USA

15:00 – 15:20 Pacing, resynchronization and ICD therapies

Ali Oto (Istanbul, Turkey)
Moataz Zaki (Alexandria, Egypt)

15:20- 15:50 Structural heart diseases

Zainab Samad (Karachi, Pakistan and Durham, USA)
Mohamed Balghaith (Riyadh, Saudi Arabia)
Hazem Khamis (Cairo, Egypt)

15:50 – 16:30 Panel Discussion: What recent technology will change the outcome of our patients?

Panelists: *(in alphabetical order)*

Ali Oto, Turkey - Amr Kamal, Egypt - Elsayed Farag, Egypt - Habib Gamra, Tunisia
- Hadi Abu Hantash, Jordan - Haitham Badran, Egypt - Hazem Khamis, Egypt -
Khaled Shokry, Egypt - Maurizio Gasparini, Italy - Moataz Zaki, Egypt - Mohamed
Balghaith, KSA - Mohamed Sanhoury, Egypt - Mohamed Sobhy, Egypt - Nabil
Farag, Egypt - Zainab Samad, Pakistan and USA

16:30 – 17:00 Lunch Break

17:00 – 19:00

Heart failure and arrhythmias

Chairpersons: *(in alphabetical order)*

Alexander Mebazaa, France - Ali Oto, Turkey - Hany Ragy, Egypt - Harun Otieno, Kenya - Magdy Abdel Hamid, Egypt - Magdy El Masry, Egypt - Mahmoud Hassanein, Egypt - Maurizio Gasparini, Italy - Ramzy El Mawardy, Egypt - Salah El Tahan, Egypt - Walid Ammar, Egypt

17:00 – 17:30 Heart Failure

Alexandre Mebazaa (Paris, France)
Mahmoud Hassanein (Alexandria, Egypt)
Gehan Ramadan (Novartis, Cairo, Egypt)

17:30 – 18:00 Atrial fibrillation and arrhythmias

Maurizio Gasparini (Milan, Italy)
Ali Oto (Istanbul, Turkey)
Gamal Shaaban (Cairo, Egypt)

18:00 – 18:30 Biomarkers, eHealth and Telemedicine

Magdy Abdel Hamid (Cairo, Egypt)
Harun Otieno (Nairobi, Kenya)
Gershim Asiki (Nairobi, Kenya)

18:30 – 19:00 Panel Discussion: Barriers of optimal management of patients with heart failure and arrhythmia in the region. Role of e-health?

Panelists: *(in alphabetical order)*

Alexander Mebazaa, France - Ali Oto, Turkey - Gamal Shaaban, Egypt - Gehan Ramadan, Egypt - Gershim Asiki, Kenya - Hany Ragy, Egypt - Harun Otieno, Kenya - Magdy Abdel Hamid, Egypt - Magdy El Masry, Egypt - Mahmoud Hassanein, Egypt - Maurizio Gasparini, Italy - Ramzy El Mawardy, Egypt - Salah El Tahan, Egypt - Walid Ammar, Egypt

THURSDAY, 13 SEPTEMBER 2018

DAY 1: CVCT Forum REGULATORY SUMMIT

Pavilion Meeting Room

Closed workshop – on invitation only

(Running simultaneously to the CVCT Forum)

This workshop is intended to make experts/representatives from regulatory bodies; competent authorities and ministries of health representatives assemble and discuss ways to learn from each other and scale up local regulations to international standards. Experts would be invited to share and debate their conclusions with health care professionals at DAY 2 public workshop (“Agenda for a competitive, quality driven clinical research in the region”)

10:00 – 11:30

Session 1: CURRENT CLINICAL TRIALS REGULATION IN THE REGION

Chairpersons: *(in alphabetical order)*

Azza Saleh, Egypt - Dina Shokry, Egypt - Ines Fradi, Tunisia - Manal Milhem, USA

10:00 – 11:00

The Role of Central Directorate of Research and Health Development (RHD-MOHP) in Clinical trials

Azza Saleh (Cairo, Egypt)

The changing landscape in Tunisia

Ines Fradi (Tunis, Tunisia)

“The Way Forward” - Expectations from the industry

Michael Nabil (Sanofi – Egypt) on Behalf of the Pharma Clinical Research Working Group

Expectations from the industry

Mouez Ben Ali (Novartis Europe, France)



CRO viewpoint

Sahar Ebrahim (IQVIA Egypt)

Mosaad Morsi (Ray, Egypt)

11:00 – 12:00 Panel Discussion: Clinical Research landscape in the Region: benchmark, trends and potential enablers

Panelists: *(in alphabetical order)*

Amr Saad, Cairo Egypt - Ashraf El Fikhy, Emmes, USA - Ashraf El Khouly, Pfizer, Egypt - Azza Saleh, Cairo, Egypt - Chokri Jeribi, Sanofi, Tunisia - Dina Shokry, Cairo, Egypt - Hala Adly, Cairo, Egypt - Ines Fradi, Tunis, Tunisia - Michael Nabil, Sanofi, Egypt - Mosaad Morsi, Ray, Egypt - Mouez Ben Ali, Novartis HQ Europe, France - Muna Al-Mahmoud, Amman, Jordan - Nancy Awad, IQVIA, UAE - Sahar Ebrahim, IQVIA Egypt

12:00 – 12:30 Coffee break

12:30 – 13:30

Opening Ceremony and Press Conference

Main Hall: Teeba Meeting Room



13:30 – 15:00

Authorization of a Clinical trial application: Best practices.

Chairpersons: *(in alphabetical order)*

Azza Saleh, Egypt - Dina Shokry, Egypt - Ines Fradi, Tunisia - Maciej Kostrubic, UK

13:30 – 13:45

How the European Regulatory Agency does it?

Maciej Kostrubic (EMA, London, UK)

13:45 – 14:00

Industry & regulatory agencies requirements, and how to close the gap?

Manal Milhem (Atlanta, USA)

14:00 – 14:15

The role of Institutional Review Boards and REC-MOHP in Clinical trials

Dina Shokry (Cairo, Egypt)

14:15 – 15:10

Panel Discussion

- CT not yet approved in other countries vs. CT approved by EMA/FDA
- Interventional vs. Observational studies
- Non-drug products: medical devices, cosmetics, food supplement

Panelists: *(in alphabetical order)*

Amr Saad, Cairo Egypt - Ashraf El Fikhy, Emmes, USA - Ashraf El Khouly, Pfizer, Egypt - Azza Saleh, Cairo, Egypt - Chokri Jeribi, Sanofi, Tunisia - Dina Shokry, Cairo, Egypt - Hala Adly, Cairo, Egypt - Ines Fradi, Tunis, Tunisia - Michael Nabil, Sanofi, Egypt - Mosaad Morsi, Ray, Egypt - Mouez Ben Ali, Novartis HQ Europe, France - Muna Al-Mahmoud, Amman, Jordan - Nancy Awad, IQVIA, UAE - Sahar Ebrahim, IQVIA Egypt

15:10 – 16:30

Bio-equivalence trials.

State of local regulations, unmet needs and future directions

Chairpersons: (in alphabetical order)

Azza Saleh, Egypt - Dina Shokry, Egypt - Ines Fradi, Tunisia - Manal Milhem, USA

15:10 - 15:25

How to conduct bioequivalence studies?

Hala Adly (Cairo Egypt)

15:25 - 16:00

Country experiences

Egypt experience

Dina Shokri (Cairo, Egypt)

Tunisian experience

Chokri Jeribi (Sanofi, Tunisia)

16:00 – 16:30

Panel discussion: How to reach harmonization?

- Specific regulation for bioequivalence center
- The case of biosimilars
- Unmet needs

Panelists: (in alphabetical order)

Amr Saad, Cairo Egypt - Ashraf El Fikhy, Emmes, USA - Ashraf El Khouly, Pfizer, Egypt - Azza Saleh, Cairo, Egypt - Chokri Jeribi, Sanofi, Tunisia - Dina Shokry, Cairo, Egypt - Hala Adly, Cairo, Egypt - Ines Fradi, Tunis, Tunisia - Michael Nabil, Sanofi, Egypt - Mosaad Morsi, Ray, Egypt - Mouez Ben Ali, Novartis HQ Europe, France - Muna Al-Mahmoud, Amman, Jordan - Nancy Awad, IQVIA, UAE - Sahar Ebrahim, IQVIA Egypt

16:30 – 17:00

Lunch Break



17:00 – 18:30

Safety, Monitoring and handling of Pharmacovigilance in clinical research

Chairpersons: *(in alphabetical order)*

Ashraf El Fiky, USA - Azza Saleh, Egypt - Dina Shokry, Egypt - Ines Fradi, Tunisia

17:00 – 17:20 Pharmacovigilance requirements within randomized clinical trials and post approval studies

Ashraf El Fiky (Emmes, Rockville, USA)

Amr Saad (Cairo, Egypt)

17:20 – 18:30 Panel discussion: Safety first. How to achieve best practice, international standard monitoring and handling of Suspected Unexpected Serious Adverse Reaction (SUSARs)

Panelists: *(in alphabetical order)*

Amr Saad, Cairo Egypt - Ashraf El Fikhy, Emmes, USA - Ashraf El Khouly, Pfizer, Egypt - Azza Saleh, Cairo, Egypt - Chokri Jeribi, Sanofi, Tunisia - Dina Shokry, Cairo, Egypt - Hala Adly, Cairo, Egypt - Ines Fradi, Tunis, Tunisia - Michael Nabil, Sanofi, Egypt - Mosaad Morsi, Ray, Egypt - Mouez Ben Ali, Novartis HQ Europe, France - Muna Al-Mahmoud, Amman, Jordan - Nancy Awad, IQVIA, UAE - Sahar Ebrahim, IQVIA Egypt

19:00-21:00

Meet the Experts – by Novartis

On invitation only

FRIDAY, 14 SEPTEMBER 2018

9:00 - 11:00

PARALLEL BREAKFAST MASTER CLASSES

Breakfast Master Class 1 – Main Hall: Teeba Meeting Room

Tips and tricks for interpreting the results of a clinical trial?

Tabassome Simon (Paris, France)

Target audiences: fellows, investigators, industry reps

Breakfast Master Class 2 – Pavilion Meeting Room

How to design, run and interpret a registry

Mohamed Hsairi (Tunis, Tunisia)

Target audiences: Senior investigators, industry medical affairs

FRIDAY, 14 SEPTEMBER 2018

CVCT WORKSHOP

Main Hall: Teeba Meeting Room

11:00 – 20:00

AGENDA FOR A COMPETITIVE, QUALITY DRIVEN CLINICAL RESEARCH IN THE
REGION

This session will bring conclusions of the Day 1 Regulatory Summit to the full CVCT audience, in a plenary session, and discuss among various stakeholders, including regulators, investigators, industry, and CROs.

Panelists:

Academy - Industry & CRO - Regulatory

11:00 – 12:30

EXECUTIVE SUMMARY OF DAY 1 REGULATORY SUMMIT

Chairpersons: *(in alphabetical order)*

Ashraf El Fiky, USA - Azza Saleh, Egypt - Dina Shokry, Egypt - Ines Fradi, Tunisia -
Maciej Kostrubic, UK - Manal Milhem, USA - Nihal El Habachi, Egypt

11:00 – 11:20 EXECUTIVE SUMMARY Regional regulatory bodies

Ines Fradi (Tunis, Tunisia)

Azza Saleh (Cairo, Egypt)

11:20 - 11:50 EXECUTIVE SUMMARY International perspective

Ashraf El Fiky (Emmes, Rockville, USA)

Manal Milhem (Atlanta, USA)

Maciej Kostrubic (EMA, London, UK)



11:50-13:00 Stakeholders' expectations

11:50- 12:20 Regulatory

International investigator viewpoint

Zainab Samad (Karachi, Pakistan and Durham, USA)

Regional investigator viewpoint

Hany Ragy (Cairo, Egypt)

**Perspective on Past and Current challenges in conducting
Clinical Trials in Egypt: 12 years' experience**

Nihal El Habachi (Alexandria Egypt)

12:20 – 12:40 Industry viewpoint

Chokri Jeribi (Sanofi, Tunisia)

Gehan Ramadan (Novartis, Egypt)

12:40 – 13:00 CRO viewpoint

Nancy Awad (IQVIA, UAE)

Souad Dziri (Eshmoun, Tunisia)

13:00 – 14:00 Discussion with the audience

14:00 – 14:30

Coffee Break

14:30 – 16:00

Specific issues

Chairpersons: *(in alphabetical order)*

Ines Fradi, Tunisia - Faiez Zannad, France - Hany Sleem Egypt

14:30 – 15:00 Biosamples transfer issues and are local core labs the solution?

Hany Sleem (Cairo, Egypt)

Heba Kassem (Alexandria, Egypt)

15:00 – 15:15 Discussion

15:15 – 15:45 The specific issues of generic drugs and biosimilars

Generics

Chokri Jeribi (Tunis, Tunisia)

Biosimilars

Mouez Ben Ali (Novartis Europe, France)

15:45 – 16:00 Discussion

16:00 – 16:30

Lunch Break

16:30 – 17:30

The Debate: Defining a regional roadmap

Chairpersons: *(in alphabetical order)*

Ashraf El Fiky, USA - Azza Saleh, Egypt - Dina Shokry, Egypt - Faiez Zannad,

France - Ghassan Kiwan, Lebanon - Ines Fradi, Tunisia - Maciej Kostrubic, UK -

Manal Milhem, USA - Wael Al Mahmeed, UAE

With participation of all Panelists (Academy, Industry & CRO, Regulatory)

17:30 – 18:00

Concluding Remarks - Highlights of the meeting

Bringing world-class research home

Faiez Zannad

CVCT chairman (Nancy, France)